NMN (Nicotinamide Mononucleotide) — Expert Claims
Extracted from publicly available podcast transcripts and videos. Each claim is attributed and sourced.
Claims are extracted using AI (Claude) from publicly available transcripts and manually reviewed. Extraction confidence (high / medium / low) indicates accuracy of capture. Each claim is compared against PubMed research.
53 expert mentions
"The practical guidance I follow is 500 milligrams to 1 gram in the morning."
Rhonda Patrick follows a practical dosing protocol of 500 milligrams to 1 gram of NMN taken in the morning.
The published research provided includes several RCTs and reviews on NMN supplementation (PMIDs 36482258, 34238308, 33888596, 38789831, 36002548), which collectively suggest NMN has been studied across a range of doses in human populations, with safety evaluations conducted in healthy adults. However, none of the retrieved study entries contain extractable key findings, population details, or dosing specifics that directly validate or contradict the 500 mg–1 g morning dosing protocol claimed by Rhonda Patrick. Without access to the actual dosing ranges, outcomes, and safety thresholds reported in these studies, it is not possible to rigorously assess whether the claimed protocol is directly supported by this body of evidence. The claim itself is a practical personal protocol rather than a clinical recommendation, which further limits direct comparability.
"The practical guidance I follow is 500 milligrams to 1 gram in the morning."
Rhonda Patrick follows a practical dosing protocol of 500 milligrams to 1 gram of NMN taken in the morning.
"I also stack NMN with resveratrol because resveratrol activates SIRT1, a sirtuin that requires NAD+ as a cofactor. They're synergistic — NMN provides the fuel, resveratrol turns the ignition."
Brecka stacks NMN with resveratrol because resveratrol activates SIRT1, a sirtuin that requires NAD+ as a cofactor, making the combination synergistic.
"I typically start clients at 500 milligrams in the morning — NAD+ has an energizing effect and taking it at night can disrupt sleep for some people."
Brecka typically starts clients on 500 milligrams of NMN in the morning, as NAD+ has an energizing effect and taking it at night can disrupt sleep for some people.
"Another trial in older adults showed improvements in gait speed and grip strength. These are meaningful functional outcomes."
Another trial in older adults showed that NMN supplementation led to improvements in gait speed and grip strength.
Study PMID 38789831 is an RCT in older adults that specifically examined NMN supplementation and found it 'maintained walking speed' (a proxy for gait speed) alongside improved sleep quality and increased blood NAD levels, which partially aligns with Patrick's claim about gait speed improvements. However, the claim also mentions grip strength improvements, and none of the listed studies explicitly report grip strength outcomes in their titles or available key findings. The evidence base is further limited by the fact that key findings, population sizes, and limitations fields are unpopulated for all studies, making precise verification difficult.
"There's a study showing improved muscle insulin sensitivity in overweight postmenopausal women"
A study showed NMN improved muscle insulin sensitivity in overweight postmenopausal women.
PMID 33888596 is an RCT directly titled 'Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women,' which closely aligns with Huberman's claim. However, the expert describes the population as 'overweight postmenopausal women,' while the study title specifies 'prediabetic women' — these populations overlap but are not identical, introducing a meaningful discrepancy in how the claim characterizes the study's population. The published metadata provided does not include detailed findings, sample size, or explicit postmenopausal status, limiting the ability to fully verify or refute the characterization. The claim is directionally supported by an identifiable RCT but contains a population descriptor that may be imprecise or partially inaccurate.
"Studies have used anywhere from 250 milligrams to 1200 milligrams per day."
Studies have used NMN doses ranging from 250 milligrams to 1200 milligrams per day, and dosing remains an open question.
The available studies include multiple RCTs and reviews examining NMN supplementation, and the published literature does reflect a range of doses across human trials consistent with Huberman's claim. For example, the dose-dependent RCT (PMID: 36482258) and the safety evaluation (PMID: 36002548) suggest dose variation has been systematically studied, while trials in prediabetic women (PMID: 33888596) and older adults (PMID: 38789831) further illustrate the range of protocols in use. However, the specific dose range of 250–1200 mg/day cannot be directly confirmed or denied from the metadata provided, as key findings, populations, and dose details are not reported in the available abstracts. The claim that dosing remains 'an open question' is broadly consistent with the lack of consensus reflected across multiple reviews and moderate-quality trials.
"some data on cardiovascular function"
There is some data on NMN and cardiovascular function.
Huberman's claim that 'there is some data on NMN and cardiovascular function' is directly supported by the available literature. PMID 39273473 is a review specifically titled 'Nicotinamide Mononucleotide: Research Process in Cardiovascular Diseases,' confirming a dedicated body of work on this topic. Additionally, PMID 36555691 addresses mitochondrial dysfunction and therapeutic perspectives in cardiovascular diseases, which is mechanistically relevant to NMN's role as an NAD+ precursor. The claim is deliberately modest ('some data'), which aligns well with the evidence base — predominantly reviews and moderate-quality RCTs rather than definitive large-scale cardiovascular outcome trials.
"a study in recreational runners showing improved aerobic capacity"
A study in recreational runners showed NMN improved aerobic capacity.
A directly relevant RCT (PMID: 34238308) titled 'Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study' appears to directly support Huberman's claim about NMN improving aerobic capacity in recreational (amateur) runners. However, the metadata provided lists no key findings, population details, or limitations for this study, preventing confirmation of effect sizes, sample size, or methodological rigor. The study is rated only 'moderate' quality, and without access to specifics such as participant numbers, duration, or magnitude of aerobic improvement, the claim cannot be fully verified despite the apparent alignment in study design and population.
"NMN supplementation in aged mice has reversed muscle wasting, improved energy metabolism, and even extended lifespan in some studies."
In aged mice, NMN supplementation has reversed muscle wasting, improved energy metabolism, and extended lifespan in some studies.
Huberman's claim specifically concerns aged mice showing muscle wasting reversal, improved energy metabolism, and lifespan extension with NMN supplementation. None of the 10 provided studies are animal studies — they are all human RCTs or reviews. The available human RCTs (PMIDs 33888596, 38789831, 34238308) examine outcomes like insulin sensitivity, walking speed, aerobic capacity, and NAD levels in humans, but do not test the specific mouse-model outcomes cited. While the human studies provide some indirect support for NMN's metabolic effects, the claim as stated references preclinical animal data that is simply not represented in the provided literature.
"A study published in Science showed that oral NMN supplementation in healthy middle-aged adults raised blood NAD+ levels in a dose-dependent manner and improved skeletal muscle insulin sensitivity."
A study published in Science showed that oral NMN supplementation in healthy middle-aged adults raised blood NAD+ levels in a dose-dependent manner and improved skeletal muscle insulin sensitivity.
The expert's claim contains two distinct assertions. The dose-dependent increase in blood NAD+ levels from oral NMN in healthy middle-aged adults is supported by the RCT listed (PMID: 36482258), which appears to be a multicenter, double-blind, placebo-controlled dose-dependent trial in that population. The improvement in skeletal muscle insulin sensitivity appears to reference the RCT (PMID: 33888596), which studied NMN and muscle insulin sensitivity, but notably that study was conducted in prediabetic women — not 'healthy middle-aged adults' as the expert states. Critically, the expert attributes the study to the journal *Science*, but the insulin sensitivity RCT (PMID: 33888596) was published in *Science* (specifically *Science* subsidiary journal), making that attribution potentially accurate; however, the population description is imprecise. The combination of both findings into a single attributed study is likely a conflation of separate research.
"There are now a handful of human clinical trials showing that oral NMN supplementation does raise blood NAD+ levels — that part seems to work."
Human clinical trials have shown that oral NMN supplementation does raise blood NAD+ levels.
Multiple RCTs in the provided evidence list appear directly relevant to the claim. PMID 38789831 is explicitly titled as showing that NMN 'increased blood NAD levels' in older adults in a double-blind, placebo-controlled study, and PMID 36482258 describes a multicenter, double-blind, placebo-controlled, dose-dependent RCT in healthy middle-aged adults that would logically assess blood NAD+ changes. However, because the 'Key finding,' 'Population,' and 'Limitations' fields are all listed as 'None' for every study in the provided data, the full details (sample sizes, magnitude of NAD+ increases, and specific populations) cannot be confirmed from the supplied records alone. The claim is therefore supported in direction by the study titles but cannot be fully verified in strength or generalizability without the complete study data.
"Another trial in older adults showed improvements in gait speed and grip strength. These are meaningful functional outcomes."
Another trial in older adults showed that NMN supplementation led to improvements in gait speed and grip strength.
"A study published in Science showed that oral NMN supplementation in healthy middle-aged adults raised blood NAD+ levels in a dose-dependent manner and improved skeletal muscle insulin sensitivity."
A study published in Science showed that oral NMN supplementation in healthy middle-aged adults raised blood NAD+ levels in a dose-dependent manner and improved skeletal muscle insulin sensitivity.
"studies in mice show reversal of aspects of vascular aging, improvement in muscle function, and metabolic benefits."
Animal studies on NMN show reversal of aspects of vascular aging, improvement in muscle function, and metabolic benefits.
"There's published data now showing NMN supplementation raises NAD+ levels in humans and improves certain markers of metabolic health and physical performance."
Published human clinical data shows NMN supplementation raises NAD+ levels and improves certain markers of metabolic health and physical performance.
"most of the human trials have used 250 to 500 milligrams per day. Some researchers use up to 1,000 milligrams."
Most human trials have used 250 to 500 milligrams per day of NMN, with some researchers using up to 1,000 milligrams.
"There are now a handful of human clinical trials showing that oral NMN supplementation does raise blood NAD+ levels — that part seems to work."
Human clinical trials have shown that oral NMN supplementation does raise blood NAD+ levels.
"NMN supplementation in aged mice has reversed muscle wasting, improved energy metabolism, and even extended lifespan in some studies."
In aged mice, NMN supplementation has reversed muscle wasting, improved energy metabolism, and extended lifespan in some studies.
"There's a study showing improved muscle insulin sensitivity in overweight postmenopausal women"
A study showed NMN improved muscle insulin sensitivity in overweight postmenopausal women.
"Studies have used anywhere from 250 milligrams to 1200 milligrams per day."
Studies have used NMN doses ranging from 250 milligrams to 1200 milligrams per day, and dosing remains an open question.
"a study in recreational runners showing improved aerobic capacity"
A study in recreational runners showed NMN improved aerobic capacity.
"some data on cardiovascular function"
There is some data on NMN and cardiovascular function.
"NMN — nicotinamide mononucleotide — is a direct precursor to NAD+. When you take NMN, your body converts it to NAD+ through a relatively efficient enzymatic pathway."
NMN is a direct precursor to NAD+, and the body converts it to NAD+ through a relatively efficient enzymatic pathway.
"The rationale for supplementing NMN is to raise NAD+ levels and potentially slow or reverse some aspects of cellular aging."
The rationale for supplementing NMN is to raise NAD+ levels and potentially slow or reverse some aspects of cellular aging.
The mechanistic rationale that NMN supplementation raises NAD+ levels is supported by multiple RCTs in the provided literature, including a study (PMID: 38789831) specifically reporting increased blood NAD levels following NMN ingestion in older adults, and safety/efficacy trials (PMIDs: 36482258, 36002548) consistent with this pathway. However, the broader claim that raising NAD+ can 'slow or reverse some aspects of cellular aging' remains a plausible but not firmly established mechanistic claim in humans — the available studies largely assess surrogate endpoints (e.g., insulin sensitivity, walking speed, aerobic capacity) rather than direct aging biomarkers, and the key findings fields are unpopulated, limiting precise assessment. The review literature (PMIDs: 39308064, 33932956, 39026037) appears to address NAD+ regulation and anti-aging effects, which would be consistent with the claim's framing, but without extractable findings these cannot be treated as direct support.
"This is in contrast to NR — nicotinamide riboside — which requires conversion to NMN first before becoming NAD+. Whether this pharmacokinetic difference has meaningful consequences for tissue NAD+ levels in humans is still debated."
NMN converts to NAD+ one step earlier in the pathway than NR, which must first be converted to NMN before becoming NAD+, though whether this pharmacokinetic difference meaningfully affects tissue NAD+ levels in humans is still debated.
The expert's claim is a mechanistic statement about the NAD+ biosynthesis pathway — specifically that NMN enters the pathway one step closer to NAD+ than NR does — which is a well-established biochemical description found in basic metabolism literature. However, none of the 10 listed studies provide extractable key findings, populations, or limitations data, making direct evidence-based comparison impossible. The RCTs (e.g., PMIDs 36482258, 38789831, 33888596) appear to measure outcomes like blood NAD levels and insulin sensitivity but do not directly compare NMN vs. NR pharmacokinetics in human tissues. The expert's secondary point — that whether this pathway difference meaningfully affects human tissue NAD+ levels remains debated — is appropriately cautious and consistent with the general state of the field.
"NMN — nicotinamide mononucleotide — is a precursor to NAD+, which stands for nicotinamide adenine dinucleotide. NAD+ is a coenzyme involved in hundreds of metabolic reactions, and its decline with age is one of the most reproduced findings in the biology of aging."
NMN is a precursor to NAD+, a coenzyme involved in hundreds of metabolic reactions whose decline with age is one of the most reproduced findings in aging biology.
Huberman's claim is mechanistic in nature, asserting that NMN is a precursor to NAD+ and that NAD+ declines with age. Multiple reviews in the provided literature (PMIDs 39026037, 33932956, 39308064) address NAD+ metabolism and its regulation, consistent with NMN's well-established role as a biosynthetic precursor to NAD+. Several RCTs (PMIDs 38789831, 36482258, 36002548) demonstrate that oral NMN supplementation raises blood NAD+ levels in human subjects, directly supporting the precursor relationship. The characterization of NAD+ decline with age as 'one of the most reproduced findings in aging biology' aligns with the breadth of review literature on this topic, though the retrieved studies lack extractable key findings to fully quantify this claim.
"This is different from taking NAD+ directly, which is poorly absorbed through the gut."
Taking NMN is advantageous over taking NAD+ directly because NAD+ is poorly absorbed through the gut.
"Sublingual or liposomal forms may have better bioavailability than standard capsules, though the data on this is not definitive."
Sublingual or liposomal forms of NMN may have better bioavailability than standard capsules, though the data on this is not definitive.
"The rationale for supplementing NMN is to raise NAD+ levels and potentially slow or reverse some aspects of cellular aging."
The rationale for supplementing NMN is to raise NAD+ levels and potentially slow or reverse some aspects of cellular aging.
"NAD+ levels in humans drop dramatically between our 20s and our 60s — estimates vary but we're talking about a 50% or greater decline in many tissues."
NAD+ levels in humans drop by 50% or more in many tissues between a person's 20s and 60s.
None of the 10 provided studies directly measure or report tissue-specific NAD+ levels across age groups (20s vs. 60s) in humans. The studies are primarily RCTs evaluating NMN supplementation outcomes and reviews of NAD+ biology, but none of the key findings fields contain data that would confirm or refute a 50% decline in tissue NAD+ levels with aging. While the claim is biologically plausible and is cited in NAD+ aging literature, the specific quantitative assertion (≥50% decline across many tissues) cannot be assessed against the provided evidence.
"NAD+ levels in humans drop dramatically between our 20s and our 60s — estimates vary but we're talking about a 50% or greater decline in many tissues."
NAD+ levels in humans drop by 50% or more in many tissues between a person's 20s and 60s.
"some researchers suggest morning dosing to align with circadian patterns of NAD+ metabolism, and some animal studies suggest NMN is absorbed better in the mornings."
Morning dosing of NMN may be preferable to align with circadian patterns of NAD+ metabolism, with some animal studies suggesting better absorption in the mornings.
None of the 10 listed studies (including RCTs such as PMIDs 36482258, 34238308, 33888596, 38789831, and 36002548, and multiple reviews) provide data on timing of NMN dosing, circadian patterns of NAD+ absorption, or morning versus evening administration. The claim references animal studies suggesting better morning absorption, but no such studies appear in the provided literature, and no human RCT in this set examines dosing time as a variable. The mechanistic premise about circadian regulation of NAD+ metabolism is plausible given known biology of the NAMPT-NAD+ axis, but the provided evidence base does not address it.
"NMN — nicotinamide mononucleotide — is a precursor that's converted to NAD+ via a single enzymatic step catalyzed by NMNAT."
NMN is a precursor that is converted to NAD+ via a single enzymatic step catalyzed by NMNAT.
The claim that NMN is converted to NAD+ via a single enzymatic step catalyzed by NMNAT is biochemically well-established in the scientific literature as part of the salvage pathway. However, none of the provided studies directly report or validate this specific mechanistic step with key findings included — all key findings, populations, and limitations fields are listed as 'None,' making direct citation impossible. The broader claim is consistent with general biochemistry underlying NMN supplementation research (e.g., PMID 36482258, 38789831 showing NMN raises blood NAD+ levels), but the provided evidence base does not explicitly confirm or detail the single-step NMNAT enzymatic conversion. Additionally, emerging research has raised questions about whether orally ingested NMN may be partially converted to nicotinamide (NAM) in the gut before entering cells, potentially complicating the 'single step' narrative.
"some researchers suggest morning dosing to align with circadian patterns of NAD+ metabolism, and some animal studies suggest NMN is absorbed better in the mornings."
Morning dosing of NMN may be preferable to align with circadian patterns of NAD+ metabolism, with some animal studies suggesting better absorption in the mornings.
"NMN — nicotinamide mononucleotide — is a precursor that's converted to NAD+ via a single enzymatic step catalyzed by NMNAT."
NMN is a precursor that is converted to NAD+ via a single enzymatic step catalyzed by NMNAT.
"This is in contrast to NR — nicotinamide riboside — which requires conversion to NMN first before becoming NAD+. Whether this pharmacokinetic difference has meaningful consequences for tissue NAD+ levels in humans is still debated."
NMN converts to NAD+ one step earlier in the pathway than NR, which must first be converted to NMN before becoming NAD+, though whether this pharmacokinetic difference meaningfully affects tissue NAD+ levels in humans is still debated.
"NMN — nicotinamide mononucleotide — is a precursor to NAD+, which stands for nicotinamide adenine dinucleotide. NAD+ is a coenzyme involved in hundreds of metabolic reactions, and its decline with age is one of the most reproduced findings in the biology of aging."
NMN is a precursor to NAD+, a coenzyme involved in hundreds of metabolic reactions whose decline with age is one of the most reproduced findings in aging biology.
"I take NMN — typically 500 to 1000 milligrams in the morning. I want to be transparent that I take it based on the mechanistic logic and the animal data, knowing the human trials are still early. I'm treating this as a calculated bet, not a proven intervention."
Huberman personally takes NMN at 500 to 1000 milligrams in the morning, based on mechanistic logic and animal data, acknowledging human trials are still early.
"I supplement with NMN and have done so for several years. I do it based on the totality of the evidence — the mechanistic rationale, the animal data, and the emerging human trials."
Rhonda Patrick personally supplements with NMN and has done so for several years, based on the mechanistic rationale, animal data, and emerging human trials.
"I supplement with NMN and have done so for several years. I do it based on the totality of the evidence — the mechanistic rationale, the animal data, and the emerging human trials."
Rhonda Patrick personally supplements with NMN and has done so for several years, based on the mechanistic rationale, animal data, and emerging human trials.
The expert's claim is a personal anecdote citing mechanistic rationale, animal data, and emerging human trials as justification for NMN supplementation. The published research provided includes several RCTs (PMIDs 36482258, 34238308, 33888596, 38789831, 36002548) that collectively suggest NMN raises blood NAD+ levels, appears safe in healthy adults, and shows signals for benefits such as improved insulin sensitivity in prediabetic women and maintained walking speed in older adults. However, the key findings, sample sizes, and populations are not detailed in the provided abstracts, limiting a precise assessment of effect sizes or generalizability. The mechanistic and animal-data rationale Patrick cites is consistent with the review literature included (PMIDs 39026037, 39308064, 33932956), though translating preclinical findings to humans remains an acknowledged challenge in the field.
"I take NMN — typically 500 to 1000 milligrams in the morning. I want to be transparent that I take it based on the mechanistic logic and the animal data, knowing the human trials are still early. I'm treating this as a calculated bet, not a proven intervention."
Huberman personally takes NMN at 500 to 1000 milligrams in the morning, based on mechanistic logic and animal data, acknowledging human trials are still early.
Huberman's claim is a personal anecdote explicitly grounded in mechanistic logic and animal data while acknowledging early-stage human evidence — which is largely accurate. The available RCTs (PMIDs 36482258, 38789831, 34238308, 33888596, 36002548) do provide some human evidence that NMN supplementation raises blood NAD+ levels and may confer modest benefits such as improved insulin sensitivity in prediabetic women and maintained walking speed in older adults, lending partial support to the biological plausibility of his approach. However, the key finding and population details for these studies are not fully specified in the provided data, limiting precise dose-response comparison with his 500–1000 mg range. His candid acknowledgment that human trials are early accurately reflects the current state of the literature, making the overall framing responsible and consistent with the evidence base.
"NAD+ has an energizing effect and taking it at night can disrupt sleep for some people."
Taking NMN at night can disrupt sleep for some people due to its energizing effect.
"Higher doses raise NAD+ more but the dose-response relationship isn't linear and there are theoretical concerns about too much NAD+ pathway activation."
Higher doses of NMN raise NAD+ more, but the dose-response relationship is not linear and there are theoretical concerns about too much NAD+ pathway activation.
The provided research list includes relevant RCTs (e.g., PMID 36482258 examining dose-dependent NMN effects, PMID 36002548 on safety, PMID 38789831 on NAD levels) and reviews that could address dose-response relationships and theoretical concerns about NAD+ pathway over-activation. However, none of the entries include populated key findings, populations, or limitations fields, making it impossible to directly verify or contradict Huberman's specific claims about non-linearity in the dose-response curve or theoretical harms from excessive NAD+ activation. The claim combines an empirical assertion (non-linear dose-response) with a theoretical safety concern, both of which require detailed study data to evaluate rigorously.
"On all three counts, NMN looks promising. That said, I want to be clear: this is not a proven anti-aging drug."
NMN looks promising based on mechanistic plausibility, safety profile, and early human data, but it is not a proven anti-aging drug.
"NMN supplementation also raises levels of NAAD and other metabolites, and the full biological effects of this aren't completely mapped out yet."
NMN supplementation also raises levels of NAAD and other metabolites, and the full biological effects of this are not completely mapped out.
Huberman's claim that NMN supplementation raises NAAD and other metabolites with incompletely mapped biological effects is a scientifically plausible and cautious statement, but the provided studies do not contain extractable key findings (all listed as 'None') that directly address NAAD elevation or the broader metabolite profile following NMN supplementation. While several RCTs (PMIDs 36482258, 38789831, 33888596, 36002548) and reviews (PMIDs 39026037, 33932956) exist in the literature that could speak to NAD metabolism and downstream metabolites, the data fields provided are empty, making it impossible to confirm or deny the specific claim about NAAD elevation from this evidence set. The claim is consistent with known NAD biosynthesis biochemistry, but direct evidentiary support cannot be established from the available abstracts as presented.
"But we don't yet have large long-term trials on hard outcomes like disease prevention or longevity in humans."
There are no large long-term human trials on hard outcomes like disease prevention or longevity from NMN.
Huberman's claim that no large long-term human trials on hard outcomes (disease prevention or longevity) exist for NMN is supported by the available evidence. The RCTs listed (PMIDs 36482258, 34238308, 33888596, 38789831, 36002548) examine surrogate or intermediate endpoints such as NAD levels, insulin sensitivity, aerobic capacity, walking speed, and safety — not hard clinical outcomes like disease prevention or longevity. The review articles (PMIDs 39026037, 39308064, 33932956, 36555691, 39273473) similarly reflect a research landscape focused on mechanistic and preliminary findings rather than large-scale outcome trials. None of the listed studies appear to be large, long-duration trials powered to detect reductions in disease incidence or mortality.
"We don't have long-term randomized controlled trials in humans showing it extends lifespan or reverses disease. The hype around NMN and NR sometimes outpaces the evidence."
There are no long-term randomized controlled trials in humans showing NMN extends lifespan or reverses disease, and the hype around NMN sometimes outpaces the evidence.
"But we don't yet have large long-term trials on hard outcomes like disease prevention or longevity in humans."
There are no large long-term human trials on hard outcomes like disease prevention or longevity from NMN.
"NMN supplementation also raises levels of NAAD and other metabolites, and the full biological effects of this aren't completely mapped out yet."
NMN supplementation also raises levels of NAAD and other metabolites, and the full biological effects of this are not completely mapped out.
"Higher doses raise NAD+ more but the dose-response relationship isn't linear and there are theoretical concerns about too much NAD+ pathway activation."
Higher doses of NMN raise NAD+ more, but the dose-response relationship is not linear and there are theoretical concerns about too much NAD+ pathway activation.
"I recognize we don't have 20-year outcomes data in humans, but the risk-benefit calculation looks favorable given what we know."
Rhonda Patrick acknowledges there are no 20-year human outcomes data for NMN, but considers the risk-benefit calculation favorable given current evidence.
Patrick's acknowledgment that long-term (20-year) human outcomes data are absent for NMN is directly supported by the available literature, which consists only of short-term RCTs and reviews. The RCTs present (PMIDs 36482258, 34238308, 33888596, 38789831, 36002548) address safety and discrete outcomes over relatively brief periods in limited populations (middle-aged adults, prediabetic women, older adults, amateur runners), none approaching long-term follow-up. The safety RCT (PMID 36002548) and the multicenter dose-dependent trial (PMID 36482258) provide some basis for a favorable near-term safety profile, which could partially support a favorable risk-benefit framing. However, the research database provided lacks detailed key findings, sample sizes, or limitation data, making it impossible to fully validate the 'favorable risk-benefit calculation' aspect of her claim with precision.
"I recognize we don't have 20-year outcomes data in humans, but the risk-benefit calculation looks favorable given what we know."
Rhonda Patrick acknowledges there are no 20-year human outcomes data for NMN, but considers the risk-benefit calculation favorable given current evidence.